神経血管デバイス/インターベンショナル・ニューロロジーの世界市場予測 2023-2032GLOBAL NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET FORECAST 2023-2032 主な調査結果 世界の神経血管デバイス/インターベンショナル神経学市場は、予測期間中にCAGR 5.23%を記録すると予測されている。この市場の成長は、世界中で神経疾患の発生率が上昇していること、低侵襲手技への... もっと見る
サマリー主な調査結果世界の神経血管デバイス/インターベンショナル神経学市場は、予測期間中にCAGR 5.23%を記録すると予測されている。この市場の成長は、世界中で神経疾患の発生率が上昇していること、低侵襲手技への嗜好が高まっていること、神経血管疾患に対する高齢者人口の脆弱性、神経血管疾患のリスクを増大させる基礎疾患などの主な促進要因によるものである。 市場洞察 神経血管疾患は、脳や脊髄に酸素を含んだ血液を供給する血管と関連している。血流が阻害されると脳機能が低下し、生命を脅かす危険性がある。このような状態では、早急な医療処置が不可欠である。頭蓋内狭窄、高悪玉コレステロール、高血圧、糖尿病などの因子が神経血管疾患の原因となる。 例えば、悪玉コレステロール値が高くなると、頭蓋内動脈にプラークが沈着し、狭窄を引き起こし、虚血性脳卒中のリスクを高める。神経血管デバイスを用いた迅速な治療は、こうした状態を管理する上で極めて重要であり、市場の成長を牽引している。さらに、虚血性脳卒中の主な原因である高血圧は、脳を供給する動脈を塞ぐ血栓を引き起こし、脳卒中を引き起こします。その結果、神経血管疾患のリスク増大につながる基礎疾患が、予測期間中の世界の神経血管機器/介入神経学市場の成長に寄与すると予想される。 地域別洞察 世界の神経血管装置/介入型神経学市場の成長評価には、欧州、アジア太平洋、北米、その他の地域の分析が含まれる。北米は2032年までに最も高い収益シェアを獲得すると予想されており、この地域の成長は神経血管疾患の増加や最先端医療技術への高い投資に起因している。 競争に関する洞察 世界の神経血管装置/介入神経学市場の主要企業は、市場シェアを拡大するために様々な戦略を実施しているため、予測期間中に業界の競争は激化するとみられる。従って、市場の上位企業には、Medtronic Inc、Memry Corporation、Penumbra Inc、MicroPort Scientific Corporationなどがあります。 当レポートの内容は以下の通りです: - 市場全体の主要調査結果の調査 - 市場ダイナミクスの戦略的内訳(促進要因、抑制要因、機会、課題) - 全セグメント、サブセグメント、地域の3年間の過去データとともに、最低9年間の市場予測 - 市場セグメンテーション:主要セグメントの徹底的な評価と市場予測 - 地域別分析:言及された地域と国レベルのセグメントを市場シェアとともに評価 - 主要分析:ポーターのファイブフォース分析、ベンダーランドスケープ、オポチュニティマトリックス、主要購買基準など。 - 競争環境は、要因や市場シェアなどに基づく主要企業の理論的説明である。 - 企業プロファイリング:詳細な会社概要、提供する製品・サービス、SCOT分析、最近の戦略的展開など 目次TABLE OF CONTENTS1. RESEARCH SCOPE & METHODOLOGY 1.1.STUDY OBJECTIVES 1.2.METHODOLOGY 1.3.ASSUMPTIONS & LIMITATIONS 2. EXECUTIVE SUMMARY 2.1.MARKET SIZE & ESTIMATES 2.2.MARKET OVERVIEW 2.3.SCOPE OF STUDY 2.4.CRISIS SCENARIO ANALYSIS 2.4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 2.5.MAJOR MARKET FINDINGS 2.5.1. GOVERNMENT INITIATIVES TO CREATE AWARENESS ABOUT NEUROVASCULAR DISEASES 2.5.2. EARLY DETECTION OF ARTERIOVENOUS MALFORMATION (AVM) 2.5.3. THROMBECTOMY IMPROVES PATIENT OUTCOMES AND REDUCES DISABILITY RATE 3. MARKET DYNAMICS 3.1.KEY DRIVERS 3.1.1. SIGNIFICANT RISE IN INCIDENCE OF NEUROVASCULAR CONDITIONS 3.1.2. PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 3.1.3. GERIATRIC POPULATION’S VULNERABILITY TO NEUROVASCULAR DISEASES 3.1.4. UNDERLYING DISEASES ARE A RISK FACTOR FOR NEUROVASCULAR DISEASES 3.2.KEY RESTRAINTS 3.2.1. EXORBITANT COSTS OF NEUROVASCULAR DEVICES 3.2.2. LACK OF TRAINED NEUROSURGEONS 4. KEY ANALYTICS 4.1.KEY MARKET TRENDS 4.2.PORTER’S FIVE FORCES ANALYSIS 4.2.1. BUYERS POWER 4.2.2. SUPPLIERS POWER 4.2.3. SUBSTITUTION 4.2.4. NEW ENTRANTS 4.2.5. INDUSTRY RIVALRY 4.3.GROWTH PROSPECT MAPPING 4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES 4.3.2. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM 4.3.3. GROWTH PROSPECT MAPPING FOR THAILAND 4.3.4. GROWTH PROSPECT MAPPING FOR MIDDLE EAST & AFRICA 4.4.MARKET MATURITY ANALYSIS 4.5.MARKET CONCENTRATION ANALYSIS 4.6.VALUE CHAIN ANALYSIS 5. MARKET BY PRODUCT 5.1.EMBOLIZATION DEVICES 5.1.1. EMBOLIC COILS 5.1.1.1. COATED DETACHABLE COILS 5.1.1.2. BARE DETACHABLE COILS 5.1.2. COIL ASSIST STENT 5.1.3. CLIPPINGS 5.1.4. COIL ASSIST BALLOON 5.2.ACCESSORY DEVICES 5.2.1. MICROCATHETERS 5.2.2. MICRO GUIDEWIRES 5.3.REVASCULARIZATION DEVICES 5.3.1. CAROTID ARTERY STENTS 5.3.2. FLOW DIVERSION STENTS 5.4.THROMBECTOMY DEVICES 5.4.1. CLOT RETRIEVAL DEVICES 5.4.2. SUCTION AND ASPIRATION DEVICES 5.4.3. SNARES 5.5.EMBOLIC PROTECTION DEVICES 5.5.1. BALLOON OCCLUSION DEVICES 5.5.2. DISTAL FILTER DEVICES 6. MARKET BY APPLICATION 6.1.ANEURYSM 6.2.ISCHEMIC STROKE 6.3.STENOSIS 6.4.ARTERIOVENOUS MALFORMATION (AVM) 6.5.OTHER APPLICATIONS 7. GEOGRAPHICAL ANALYSIS 7.1.NORTH AMERICA 7.1.1. MARKET SIZE & ESTIMATES 7.1.2. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.1.3. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.1.4. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.1.5. KEY PLAYERS IN NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.1.6. COUNTRY ANALYSIS 7.1.6.1. UNITED STATES 7.1.6.1.1. UNITED STATES NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.1.6.2. CANADA 7.1.6.2.1. CANADA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.EUROPE 7.2.1. MARKET SIZE & ESTIMATES 7.2.2. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.2.3. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.2.4. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.2.5. KEY PLAYERS IN EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.2.6. COUNTRY ANALYSIS 7.2.6.1. UNITED KINGDOM 7.2.6.1.1. UNITED KINGDOM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.2. GERMANY 7.2.6.2.1. GERMANY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.3. FRANCE 7.2.6.3.1. FRANCE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.4. ITALY 7.2.6.4.1. ITALY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.5. SPAIN 7.2.6.5.1. SPAIN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.6. POLAND 7.2.6.6.1. POLAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.7. BELGIUM 7.2.6.7.1. BELGIUM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.8. REST OF EUROPE 7.2.6.8.1. REST OF EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.ASIA-PACIFIC 7.3.1. MARKET SIZE & ESTIMATES 7.3.2. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.3.3. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.3.4. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.3.5. KEY PLAYERS IN ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.3.6. COUNTRY ANALYSIS 7.3.6.1. CHINA 7.3.6.1.1. CHINA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.2. JAPAN 7.3.6.2.1. JAPAN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.3. INDIA 7.3.6.3.1. INDIA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.4. SOUTH KOREA 7.3.6.4.1. SOUTH KOREA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.5. INDONESIA 7.3.6.5.1. INDONESIA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.6. THAILAND 7.3.6.6.1. THAILAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.7. VIETNAM 7.3.6.7.1. VIETNAM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.8. AUSTRALIA & NEW ZEALAND 7.3.6.8.1. AUSTRALIA & NEW ZEALAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.9. REST OF ASIA-PACIFIC 7.3.6.9.1. REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.4.REST OF WORLD 7.4.1. MARKET SIZE & ESTIMATES 7.4.2. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.4.3. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.4.4. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.4.5. KEY PLAYERS IN REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.4.6. REGIONAL ANALYSIS 7.4.6.1. LATIN AMERICA 7.4.6.1.1. LATIN AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.4.6.2. MIDDLE EAST & AFRICA 7.4.6.2.1. MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 8. COMPETITIVE LANDSCAPE 8.1.KEY STRATEGIC DEVELOPMENTS 8.1.1. MERGERS & ACQUISITIONS 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS 8.1.3. PARTNERSHIPS & AGREEMENTS 8.1.4. BUSINESS EXPANSIONS & DIVESTITURES 8.2.COMPANY PROFILES 8.2.1. ACANDIS GMBH 8.2.1.1. COMPANY OVERVIEW 8.2.1.2. PRODUCT LIST 8.2.2. ASAHI INTECC 8.2.2.1. COMPANY OVERVIEW 8.2.2.2. PRODUCT LIST 8.2.3. BALT 8.2.3.1. COMPANY OVERVIEW 8.2.3.2. PRODUCT LIST 8.2.4. B BRAUN MELSUNGEN AG 8.2.4.1. COMPANY OVERVIEW 8.2.4.2. PRODUCT LIST 8.2.4.3. STRENGTHS & CHALLENGES 8.2.5. INTEGER HOLDINGS CORPORATION 8.2.5.1. COMPANY OVERVIEW 8.2.5.2. PRODUCT LIST 8.2.5.3. STRENGTHS & CHALLENGES 8.2.6. JOHNSON & JOHNSON (CERENOVUS) 8.2.6.1. COMPANY OVERVIEW 8.2.6.2. PRODUCT LIST 8.2.6.3. STRENGTHS & CHALLENGES 8.2.7. KANEKA CORPORATION 8.2.7.1. COMPANY OVERVIEW 8.2.7.2. PRODUCT LIST 8.2.8. MEDTRONIC INC 8.2.8.1. COMPANY OVERVIEW 8.2.8.2. PRODUCT LIST 8.2.8.3. STRENGTHS & CHALLENGES 8.2.9. MEMRY CORPORATION 8.2.9.1. COMPANY OVERVIEW 8.2.9.2. PRODUCT LIST 8.2.10. MICROPORT SCIENTIFIC CORPORATION 8.2.10.1. COMPANY OVERVIEW 8.2.10.2. PRODUCT LIST 8.2.10.3. STRENGTHS & CHALLENGES 8.2.11. PENUMBRA INC 8.2.11.1. COMPANY OVERVIEW 8.2.11.2. PRODUCT LIST 8.2.12. PHENOX INC 8.2.12.1. COMPANY OVERVIEW 8.2.12.2. PRODUCT LIST 8.2.12.3. STRENGTHS & CHALLENGES 8.2.13. RAPID MEDICAL 8.2.13.1. COMPANY OVERVIEW 8.2.13.2. PRODUCT LIST 8.2.13.3. STRENGTHS & CHALLENGES 8.2.14. SENSOME 8.2.14.1. COMPANY OVERVIEW 8.2.14.2. PRODUCT LIST 8.2.14.3. STRENGTHS & CHALLENGES 8.2.15. STRYKER CORPORATION 8.2.15.1. COMPANY OVERVIEW 8.2.15.2. PRODUCT LIST 8.2.15.3. STRENGTHS & CHALLENGES 8.2.16. TERUMO CORPORATION 8.2.16.1. COMPANY OVERVIEW 8.2.16.2. PRODUCT LIST 8.2.16.3. STRENGTHS & CHALLENGES
SummaryKEY FINDINGS Table of ContentsTABLE OF CONTENTS1. RESEARCH SCOPE & METHODOLOGY 1.1.STUDY OBJECTIVES 1.2.METHODOLOGY 1.3.ASSUMPTIONS & LIMITATIONS 2. EXECUTIVE SUMMARY 2.1.MARKET SIZE & ESTIMATES 2.2.MARKET OVERVIEW 2.3.SCOPE OF STUDY 2.4.CRISIS SCENARIO ANALYSIS 2.4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 2.5.MAJOR MARKET FINDINGS 2.5.1. GOVERNMENT INITIATIVES TO CREATE AWARENESS ABOUT NEUROVASCULAR DISEASES 2.5.2. EARLY DETECTION OF ARTERIOVENOUS MALFORMATION (AVM) 2.5.3. THROMBECTOMY IMPROVES PATIENT OUTCOMES AND REDUCES DISABILITY RATE 3. MARKET DYNAMICS 3.1.KEY DRIVERS 3.1.1. SIGNIFICANT RISE IN INCIDENCE OF NEUROVASCULAR CONDITIONS 3.1.2. PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 3.1.3. GERIATRIC POPULATION’S VULNERABILITY TO NEUROVASCULAR DISEASES 3.1.4. UNDERLYING DISEASES ARE A RISK FACTOR FOR NEUROVASCULAR DISEASES 3.2.KEY RESTRAINTS 3.2.1. EXORBITANT COSTS OF NEUROVASCULAR DEVICES 3.2.2. LACK OF TRAINED NEUROSURGEONS 4. KEY ANALYTICS 4.1.KEY MARKET TRENDS 4.2.PORTER’S FIVE FORCES ANALYSIS 4.2.1. BUYERS POWER 4.2.2. SUPPLIERS POWER 4.2.3. SUBSTITUTION 4.2.4. NEW ENTRANTS 4.2.5. INDUSTRY RIVALRY 4.3.GROWTH PROSPECT MAPPING 4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES 4.3.2. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM 4.3.3. GROWTH PROSPECT MAPPING FOR THAILAND 4.3.4. GROWTH PROSPECT MAPPING FOR MIDDLE EAST & AFRICA 4.4.MARKET MATURITY ANALYSIS 4.5.MARKET CONCENTRATION ANALYSIS 4.6.VALUE CHAIN ANALYSIS 5. MARKET BY PRODUCT 5.1.EMBOLIZATION DEVICES 5.1.1. EMBOLIC COILS 5.1.1.1. COATED DETACHABLE COILS 5.1.1.2. BARE DETACHABLE COILS 5.1.2. COIL ASSIST STENT 5.1.3. CLIPPINGS 5.1.4. COIL ASSIST BALLOON 5.2.ACCESSORY DEVICES 5.2.1. MICROCATHETERS 5.2.2. MICRO GUIDEWIRES 5.3.REVASCULARIZATION DEVICES 5.3.1. CAROTID ARTERY STENTS 5.3.2. FLOW DIVERSION STENTS 5.4.THROMBECTOMY DEVICES 5.4.1. CLOT RETRIEVAL DEVICES 5.4.2. SUCTION AND ASPIRATION DEVICES 5.4.3. SNARES 5.5.EMBOLIC PROTECTION DEVICES 5.5.1. BALLOON OCCLUSION DEVICES 5.5.2. DISTAL FILTER DEVICES 6. MARKET BY APPLICATION 6.1.ANEURYSM 6.2.ISCHEMIC STROKE 6.3.STENOSIS 6.4.ARTERIOVENOUS MALFORMATION (AVM) 6.5.OTHER APPLICATIONS 7. GEOGRAPHICAL ANALYSIS 7.1.NORTH AMERICA 7.1.1. MARKET SIZE & ESTIMATES 7.1.2. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.1.3. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.1.4. NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.1.5. KEY PLAYERS IN NORTH AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.1.6. COUNTRY ANALYSIS 7.1.6.1. UNITED STATES 7.1.6.1.1. UNITED STATES NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.1.6.2. CANADA 7.1.6.2.1. CANADA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.EUROPE 7.2.1. MARKET SIZE & ESTIMATES 7.2.2. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.2.3. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.2.4. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.2.5. KEY PLAYERS IN EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.2.6. COUNTRY ANALYSIS 7.2.6.1. UNITED KINGDOM 7.2.6.1.1. UNITED KINGDOM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.2. GERMANY 7.2.6.2.1. GERMANY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.3. FRANCE 7.2.6.3.1. FRANCE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.4. ITALY 7.2.6.4.1. ITALY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.5. SPAIN 7.2.6.5.1. SPAIN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.6. POLAND 7.2.6.6.1. POLAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.7. BELGIUM 7.2.6.7.1. BELGIUM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.2.6.8. REST OF EUROPE 7.2.6.8.1. REST OF EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.ASIA-PACIFIC 7.3.1. MARKET SIZE & ESTIMATES 7.3.2. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.3.3. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.3.4. ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.3.5. KEY PLAYERS IN ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.3.6. COUNTRY ANALYSIS 7.3.6.1. CHINA 7.3.6.1.1. CHINA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.2. JAPAN 7.3.6.2.1. JAPAN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.3. INDIA 7.3.6.3.1. INDIA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.4. SOUTH KOREA 7.3.6.4.1. SOUTH KOREA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.5. INDONESIA 7.3.6.5.1. INDONESIA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.6. THAILAND 7.3.6.6.1. THAILAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.7. VIETNAM 7.3.6.7.1. VIETNAM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.8. AUSTRALIA & NEW ZEALAND 7.3.6.8.1. AUSTRALIA & NEW ZEALAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.3.6.9. REST OF ASIA-PACIFIC 7.3.6.9.1. REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.4.REST OF WORLD 7.4.1. MARKET SIZE & ESTIMATES 7.4.2. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS 7.4.3. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES 7.4.4. REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK 7.4.5. KEY PLAYERS IN REST OF WORLD NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET 7.4.6. REGIONAL ANALYSIS 7.4.6.1. LATIN AMERICA 7.4.6.1.1. LATIN AMERICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 7.4.6.2. MIDDLE EAST & AFRICA 7.4.6.2.1. MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES 8. COMPETITIVE LANDSCAPE 8.1.KEY STRATEGIC DEVELOPMENTS 8.1.1. MERGERS & ACQUISITIONS 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS 8.1.3. PARTNERSHIPS & AGREEMENTS 8.1.4. BUSINESS EXPANSIONS & DIVESTITURES 8.2.COMPANY PROFILES 8.2.1. ACANDIS GMBH 8.2.1.1. COMPANY OVERVIEW 8.2.1.2. PRODUCT LIST 8.2.2. ASAHI INTECC 8.2.2.1. COMPANY OVERVIEW 8.2.2.2. PRODUCT LIST 8.2.3. BALT 8.2.3.1. COMPANY OVERVIEW 8.2.3.2. PRODUCT LIST 8.2.4. B BRAUN MELSUNGEN AG 8.2.4.1. COMPANY OVERVIEW 8.2.4.2. PRODUCT LIST 8.2.4.3. STRENGTHS & CHALLENGES 8.2.5. INTEGER HOLDINGS CORPORATION 8.2.5.1. COMPANY OVERVIEW 8.2.5.2. PRODUCT LIST 8.2.5.3. STRENGTHS & CHALLENGES 8.2.6. JOHNSON & JOHNSON (CERENOVUS) 8.2.6.1. COMPANY OVERVIEW 8.2.6.2. PRODUCT LIST 8.2.6.3. STRENGTHS & CHALLENGES 8.2.7. KANEKA CORPORATION 8.2.7.1. COMPANY OVERVIEW 8.2.7.2. PRODUCT LIST 8.2.8. MEDTRONIC INC 8.2.8.1. COMPANY OVERVIEW 8.2.8.2. PRODUCT LIST 8.2.8.3. STRENGTHS & CHALLENGES 8.2.9. MEMRY CORPORATION 8.2.9.1. COMPANY OVERVIEW 8.2.9.2. PRODUCT LIST 8.2.10. MICROPORT SCIENTIFIC CORPORATION 8.2.10.1. COMPANY OVERVIEW 8.2.10.2. PRODUCT LIST 8.2.10.3. STRENGTHS & CHALLENGES 8.2.11. PENUMBRA INC 8.2.11.1. COMPANY OVERVIEW 8.2.11.2. PRODUCT LIST 8.2.12. PHENOX INC 8.2.12.1. COMPANY OVERVIEW 8.2.12.2. PRODUCT LIST 8.2.12.3. STRENGTHS & CHALLENGES 8.2.13. RAPID MEDICAL 8.2.13.1. COMPANY OVERVIEW 8.2.13.2. PRODUCT LIST 8.2.13.3. STRENGTHS & CHALLENGES 8.2.14. SENSOME 8.2.14.1. COMPANY OVERVIEW 8.2.14.2. PRODUCT LIST 8.2.14.3. STRENGTHS & CHALLENGES 8.2.15. STRYKER CORPORATION 8.2.15.1. COMPANY OVERVIEW 8.2.15.2. PRODUCT LIST 8.2.15.3. STRENGTHS & CHALLENGES 8.2.16. TERUMO CORPORATION 8.2.16.1. COMPANY OVERVIEW 8.2.16.2. PRODUCT LIST 8.2.16.3. STRENGTHS & CHALLENGES
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野の最新刊レポート
Inkwood Research社の分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Inkwood Research社はどのような調査会社ですか?Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/26 10:26 155.24 円 162.59 円 197.14 円 |